Peter is a pulmonary and critical care physician, writer, and recognized health policy expert on federal regulatory processes related to prescription drug pricing and reimbursement. His research has been published in numerous peer-reviewed journals, including the New England Journal of Medicine and Journal of the American Medical Association, as well as in the New York Times, New York Magazine, Wall Street Journal, Bloomberg. PR Week named him as one of the top 50 health influencers of 2021 for his work on aligning cost of care with clinical value, just ahead of Demi Lovato.
Throughout his education and career, Peter has focused on health disparities, disease prevention, and treatment access. In a highly publicized and unprecedented move, Peter and his colleagues announced in 2012 MSKCC would not cover Zaltrap, a drug with no improved clinical outcomes but double the cost of the standard of care. This controversy led to the development of a price tracking database and the founding of the Drug Pricing Lab in 2015.
In addition to leading the Center for Health Policy and Outcomes and Drug Pricing Lab, Peter is a tenured faculty member at MSKCC, full professor at Weill Cornell Medical College, and Senior Scholar at the International Agency for Research on Cancer. He has been inducted into the National Academic of Medicine, American Society of Clinical Investigators, and the Johns Hopkins University Society of Scholars, and served as Senior Advisor to the Administrator on healthcare quality and cancer policy at the Center for Medicare and Medicaid Services (2005-2006).
He completed his undergraduate studies at Harvard College, master’s in public policy from the University of Chicago, and medical degree from the University of Minnesota, and trained at Johns Hopkins Medical Center.
Disclosures (2018-present):
Speaking: Mercer Consulting, United Rheumatology, Morgan Stanley, NYS Rheumatology, Oppenheimer & Co., Cello Health (formerly Defined Health), Oncology Analytics, Anthem, Magellan Health, Kaiser Permanente Institute for Health Policy, America’s Health Insurance Plans, Geisinger, Meyer Cancer Center of Weill Cornell Medicine, National Pharmaceutical Council
Advisory: EQRx, GRAIL, Foundation Medicine
Board of Directors: Oncology Analytics
Funding: Arnold Ventures, Kaiser Permanente, National Cancer Institute, Conquer Cancer Foundation
